Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals

  • Javier Arranz-Nicolás
  • Jesús Ogando
  • Denise Soutar
  • Raquel Arcos-Pérez
  • Daniel Meraviglia-Crivelli
  • Santos Mañes
  • Isabel Mérida
  • Antonia Ávila-Flores
Original Article

Abstract

The arsenal of cancer therapies has evolved to target T lymphocytes and restore their capacity to destroy tumor cells. T cells rely on diacylglycerol (DAG) to carry out their functions. DAG availability and signaling are regulated by the enzymes diacylglycerol kinase (DGK) α and ζ, whose excess function drives T cells into hyporesponsive states. Targeting DGKα is a promising strategy for coping with cancer; its blockade could reinstate T-cell attack on tumors while limiting tumor growth, due to positive DGKα functions in several oncogenic pathways. Here, we made a side-by-side comparison of the effects of commercial pharmacological DGK inhibitors on T-cell responses with those promoted by DGKα and DGKζ genetic deletion or silencing. We show the specificity for DGKα of DGK inhibitors I and II and the structurally similar compound ritanserin. Inhibitor treatment promoted Ras/ERK (extracellular signal-regulated kinase) signaling and AP-1 (Activator protein-1) transcription, facilitated DGKα membrane localization, reduced the requirement for costimulation, and cooperated with enhanced activation following DGKζ silencing/deletion. DGKiII and ritanserin had similar effects on TCR proximal signaling, but ritanserin counteracted long-term T-cell activation, an effect that was potentiated in DGKα−/− cells. In contrast with enhanced activation triggered by pharmacological inhibition, DGKα silencing/genetic deletion led to impaired Lck (lymphocyte-specific protein tyrosine kinase) activation and limited costimulation responses. Our results demonstrate that pharmacological inhibition of DGKα downstream of the TCR provides a gain-of-function effect that amplifies the DAG-dependent signaling cascade, an ability that could be exploited therapeutically to reinvigorate T cells to attack tumors.

Keywords

Diacylglycerol kinase Cancer immunotherapy Lck T-cell activation R59949 Serotonin receptors 

Abbreviations

5-HT

Serotonin

5-HTR

Serotonin receptor

AP-1

Activator protein-1

CNB

Centro Nacional de Biotecnología

CSIC

Consejo Superior de Investigaciones Científicas

DAG

Diacylglycerol

DGK

Diacylglycerol kinase

DGKi

DGK inhibitor

ERK

Extracellular signal-regulated kinase

HM-1

Human muscarinic receptor-1

Lck

Lymphocyte-specific protein tyrosine kinase

NFAT

Nuclear factor of activated T cells

PLC

Phospholipase C-gamma

WT

Wild type

Notes

Acknowledgements

We thank Rosa Liébana for maintenance of the mouse colonies and technical assistance in the isolation of mouse cells, Alejandra Cordero for technical assistance, Carmen Moreno for technical assistance in cytometry data acquisition, and Catherine Mark for excellent editorial assistance.

Author contributions

Javier Arranz-Nicolás and Antonia Ávila-Flores performed mouse and Jurkat cell experiments, acquired, analyzed and interpreted data, and prepared the figures. Jesús Ogando performed the PBMC experiments and acquired the data. Jesús Ogando and Santos Mañes interpreted the PBMC data. Denise Soutar performed mouse experiments. Daniel Meraviglia-Crivelli and Raquel Arcos-Pérez performed Jurkat and mouse cells RT-PCR experiments. Raquel Arcos-Pérez developed the luciferase constructs. Antonia Ávila-Flores and Isabel Mérida designed and supervised the study, interpreted the data and wrote the manuscript. All authors read and gave input on the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no potential conflicts of interest.

Ethical approval

Mice were maintained and handled in accordance with Spanish and European directives. All procedures performed with animals were conducted according the protocols approved by the CNB/CSIC Ethics Committee on Animal Experimentation (RD53/2013). PBMC were from the Blood Transfusion Center, Red Cross (Madrid, Spain), obtained with appropriate informed consent from the donors. No personal data were registered and all procedures performed with these cells were in accordance with the ethical standards of the CNB/CSIC Ethics Committee.

Animal source

C57BL/6J-DGKα−/− mice were kindly donated by Dr. Xiao-Ping Zhong (Duke University Medical Center, Durham NC). C57BL/6J-DGKζ−/− mice were a gift of Dr. Gary Koretzky (University of Pennsylvania, Philadelphia PA). These mouse lines were used to generate the corresponding OT-I DGK−/− mice. The colonies were maintained in pathogen-free conditions in the CNB animal facility, following institutional guidelines.

Cell line authentication

Human leukemic Jurkat T cells were authenticated by polymorphic short tandem repeat (STR) locus analysis (Genomics Service, Centro de Investigaciones Biomédicas-CSIC).

Supplementary material

262_2018_2154_MOESM1_ESM.pdf (2.5 mb)
Supplementary material 1 (PDF 2567 KB)

References

  1. 1.
    Singh N, Frey NV, Grupp SA, Maude SL (2016) CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Curr Treat Options Oncol 17(6):28.  https://doi.org/10.1007/s11864-016-0406-4 CrossRefPubMedGoogle Scholar
  2. 2.
    Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264.  https://doi.org/10.1038/nrc3239 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384(9948):1109–1117.  https://doi.org/10.1016/S0140-6736(14)60958-2 CrossRefPubMedGoogle Scholar
  4. 4.
    Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384.  https://doi.org/10.1016/S1470-2045(15)70076-8 CrossRefPubMedGoogle Scholar
  5. 5.
    Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Pure E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20(16):4262–4273.  https://doi.org/10.1158/1078-0432.CCR-13-2627 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Merida I, Avila-Flores A, Merino E (2008) Diacylglycerol kinases: at the hub of cell signalling. Biochem J 409(1):1–18CrossRefPubMedGoogle Scholar
  7. 7.
    Merida I, Andrada E, Gharbi SI, Avila-Flores A (2015) Redundant and specialized roles for diacylglycerol kinases alpha and zeta in the control of T cell functions. Sci Signal 8(374):re6.  https://doi.org/10.1126/scisignal.aaa0974 CrossRefPubMedGoogle Scholar
  8. 8.
    Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A (2002) Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109(6):719–731CrossRefPubMedGoogle Scholar
  9. 9.
    Olenchock BA, Guo R, Carpenter JH, Jordan M, Topham MK, Koretzky GA, Zhong XP (2006) Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat Immunol 7(11):1174–1181CrossRefPubMedGoogle Scholar
  10. 10.
    Prinz PU, Mendler AN, Masouris I, Durner L, Oberneder R, Noessner E (2012) High DGK-alpha and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8 + T cells that is reversible by pharmacologic intervention. J Immunol 188(12):5990–6000.  https://doi.org/10.4049/jimmunol.1103028 CrossRefPubMedGoogle Scholar
  11. 11.
    Sato M, Liu K, Sasaki S, Kunii N, Sakai H, Mizuno H, Saga H, Sakane F (2013) Evaluations of the selectivities of the diacylglycerol kinase inhibitors R59022 and R59949 among diacylglycerol kinase isozymes using a new non-radioactive assay method. Pharmacology 92(1–2):99–107.  https://doi.org/10.1159/000351849 CrossRefPubMedGoogle Scholar
  12. 12.
    Chauveau A, Le Floc’h A, Bantilan NS, Koretzky GA, Huse M (2014) Diacylglycerol kinase alpha establishes T cell polarity by shaping diacylglycerol accumulation at the immunological synapse. Sci Signal 7(340):ra82.  https://doi.org/10.1126/scisignal.2005287 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27(6):600–611PubMedGoogle Scholar
  14. 14.
    Akhondzadeh S, Mohajari H, Reza Mohammadi M, Amini H (2003) Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. BMC Psychiatry 3:7.  https://doi.org/10.1186/1471-244X-3-7 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Boroda S, Niccum M, Raje V, Purow BW, Harris TE (2017) Dual activities of ritanserin and R59022 as DGKalpha inhibitors and serotonin receptor antagonists. Biochem Pharmacol 123:29–39.  https://doi.org/10.1016/j.bcp.2016.10.011 CrossRefPubMedGoogle Scholar
  16. 16.
    Jiang Y, Sakane F, Kanoh H, Walsh JP (2000) Selectivity of the diacylglycerol kinase inhibitor 3-[2-(4-[bis-(4-fluorophenyl)methylene]-1-piperidinyl)ethyl]-2, 3-dihydro-2-thioxo-4(1H)quinazolinone (R59949) among diacylglycerol kinase subtypes. Biochem Pharmacol 59(7):763–772CrossRefPubMedGoogle Scholar
  17. 17.
    Purow B (2015) Molecular pathways: targeting diacylglycerol kinase alpha in cancer. Clin Cancer Res 21(22):5008–5012.  https://doi.org/10.1158/1078-0432.CCR-15-0413 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Martinez-Moreno M, Garcia-Lievana J, Soutar D, Torres-Ayuso P, Andrada E, Zhong XP, Koretzky GA, Merida I, Avila-Flores A (2012) FoxO-dependent regulation of diacylglycerol kinase alpha gene expression. Mol Cell Biol 32(20):4168–4180.  https://doi.org/10.1128/MCB.00654-12 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ávila-Flores A, Arranz-Nicolás J, Andrada E, Soutar D, Mérida I (2017) Predominant contribution of DGKζ over DGKα in the control of PKC/PDK-1-regulated functions in T cells. Immunol Cell Biol 95(6):549–563.  https://doi.org/10.1038/icb.2017.7 CrossRefPubMedGoogle Scholar
  20. 20.
    Desai DM, Newton ME, Kadlecek T, Weiss A (1990) Stimulation of the phosphatidylinositol pathway can induce T-cell activation. Nature 348(6296):66–69.  https://doi.org/10.1038/348066a0 CrossRefPubMedGoogle Scholar
  21. 21.
    Sanjuan MA, Jones DR, Izquierdo M, Merida I (2001) Role of diacylglycerol kinase alpha in the attenuation of receptor signaling. J Cell Biol 153(1):207–220CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Schaap D, van der Wal J, van Blitterswijk WJ, van der Bend RL, Ploegh HL (1993) Diacylglycerol kinase is phosphorylated in vivo upon stimulation of the epidermal growth factor receptor and serine/threonine kinases, including protein kinase C-epsilon. Biochem J 289(Pt 3):875–881CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Sanjuan MA, Pradet-Balade B, Jones DR, Martinez AC, Stone JC, Garcia-Sanz JA, Merida I (2003) T cell activation in vivo targets diacylglycerol kinase alpha to the membrane: a novel mechanism for Ras attenuation. J Immunol 170(6):2877–2883CrossRefPubMedGoogle Scholar
  24. 24.
    Aune TM, Kelley KA, Ranges GE, Bombara MP (1990) Serotonin-activated signal transduction via serotonin receptors on Jurkat cells. J Immunol 145(6):1826–1831PubMedGoogle Scholar
  25. 25.
    Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360.  https://doi.org/10.1146/annurev.immunol.22.012703.104803 CrossRefPubMedGoogle Scholar
  26. 26.
    Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76(1):17–27CrossRefPubMedGoogle Scholar
  27. 27.
    Riese MJ, Grewal J, Das J, Zou T, Patil V, Chakraborty AK, Koretzky GA (2011) Decreased diacylglycerol metabolism enhances ERK activation and augments CD8 + T cell functional responses. J Biol Chem 286(7):5254–5265.  https://doi.org/10.1074/jbc.M110.171884 CrossRefPubMedGoogle Scholar
  28. 28.
    Merino E, Avila-Flores A, Shirai Y, Moraga I, Saito N, Merida I (2008) Lck-dependent tyrosine phosphorylation of diacylglycerol kinase alpha regulates its membrane association in T cells. J Immunol 180(9):5805–5815CrossRefPubMedGoogle Scholar
  29. 29.
    Torres-Ayuso P, Daza-Martin M, Martin-Perez J, Avila-Flores A, Merida I (2014) Diacylglycerol kinase alpha promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src. Oncotarget 5(20):9710–9726.  https://doi.org/10.18632/oncotarget.2344 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Stefanova I, Hemmer B, Vergelli M, Martin R, Biddison WE, Germain RN (2003) TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 4(3):248–254.  https://doi.org/10.1038/ni895 CrossRefPubMedGoogle Scholar
  31. 31.
    Wang H, Kadlecek TA, Au-Yeung BB, Goodfellow HE, Hsu LY, Freedman TS, Weiss A (2010) ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol 2(5):a002279.  https://doi.org/10.1101/cshperspect.a002279 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Inoue M, Okazaki T, Kitazono T, Mizushima M, Omata M, Ozaki S (2011) Regulation of antigen-specific CTL and Th1 cell activation through 5-Hydroxytryptamine 2A receptor. Int Immunopharmacol 11(1):67–73.  https://doi.org/10.1016/j.intimp.2010.10.007 CrossRefPubMedGoogle Scholar
  33. 33.
    Leon-Ponte M, Ahern GP, O’Connell PJ (2007) Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood 109(8):3139–3146.  https://doi.org/10.1182/blood-2006-10-052787 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Young MR, Kut JL, Coogan MP, Wright MA, Young ME, Matthews J (1993) Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low-dose exogenous serotonin. Immunology 80(3):395–400PubMedPubMedCentralGoogle Scholar
  35. 35.
    Liao W, Lin JX, Leonard WJ (2013) Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38(1):13–25.  https://doi.org/10.1016/j.immuni.2013.01.004 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Zhong XP, Hainey EA, Olenchock BA, Jordan MS, Maltzman JS, Nichols KE, Shen H, Koretzky GA (2003) Enhanced T cell responses due to diacylglycerol kinase zeta deficiency. Nat Immunol 4(9):882–890CrossRefPubMedGoogle Scholar
  37. 37.
    Bardhan K, Anagnostou T, Boussiotis VA (2016) The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front Immunol 7:550.  https://doi.org/10.3389/fimmu.2016.00550 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173(2):945–954CrossRefPubMedGoogle Scholar
  39. 39.
    Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, Karoly ED, Freeman GJ, Petkova V, Seth P, Li L, Boussiotis VA (2015) PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 6:6692.  https://doi.org/10.1038/ncomms7692 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Gharbi SI, Rincon E, Avila-Flores A, Torres-Ayuso P, Almena M, Cobos MA, Albar JP, Merida I (2011) Diacylglycerol kinase zeta controls diacylglycerol metabolism at the immunological synapse. Mol Biol Cell 22(22):4406–4414.  https://doi.org/10.1091/mbc.E11-03-0247 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Joshi RP, Schmidt AM, Das J, Pytel D, Riese MJ, Lester M, Diehl JA, Behrens EM, Kambayashi T, Koretzky GA (2013) The zeta isoform of diacylglycerol kinase plays a predominant role in regulatory T cell development and TCR-mediated ras signaling. Sci Signal 6(303):ra102.  https://doi.org/10.1126/scisignal.2004373 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Baldanzi G, Pighini A, Bettio V, Rainero E, Traini S, Chianale F, Porporato PE, Filigheddu N, Mesturini R, Song S, Schweighoffer T, Patrussi L, Baldari CT, Zhong XP, van Blitterswijk WJ, Sinigaglia F, Nichols KE, Rubio I, Parolini O, Graziani A (2011) SAP-mediated inhibition of diacylglycerol kinase alpha regulates TCR-induced diacylglycerol signaling. J Immunol 187(11):5941–5951.  https://doi.org/10.4049/jimmunol.1002476 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Prinz PU, Mendler AN, Brech D, Masouris I, Oberneder R, Noessner E (2014) NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention. Int J Cancer 135(8):1832–1841.  https://doi.org/10.1002/ijc.28837 CrossRefPubMedGoogle Scholar
  44. 44.
    Dominguez CL, Floyd DH, Xiao A, Mullins GR, Kefas BA, Xin W, Yacur MN, Abounader R, Lee JK, Wilson GM, Harris TE, Purow BW (2013) Diacylglycerol kinase alpha is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov 3(7):782–797.  https://doi.org/10.1158/2159-8290.CD-12-0215 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Franks CE, Campbell ST, Purow BW, Harris TE, Hsu KL (2017) The ligand binding landscape of diacylglycerol kinases. Cell Chem Biol 24(7):870–880.e5.  https://doi.org/10.1016/j.chembiol.2017.06.007 CrossRefPubMedGoogle Scholar
  46. 46.
    Xie S, Naslavsky N, Caplan S (2014) Diacylglycerol kinase alpha regulates tubular recycling endosome biogenesis and major histocompatibility complex class I recycling. J Biol Chem 289(46):31914–31926.  https://doi.org/10.1074/jbc.M114.594291 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Rainero E, Caswell PT, Muller PA, Grindlay J, McCaffrey MW, Zhang Q, Wakelam MJ, Vousden KH, Graziani A, Norman JC (2012) Diacylglycerol kinase alpha controls RCP-dependent integrin trafficking to promote invasive migration. J Cell Biol 196(2):277–295.  https://doi.org/10.1083/jcb.201109112 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Guo R, Wan CK, Carpenter JH, Mousallem T, Boustany RM, Kuan CT, Burks AW, Zhong XP (2008) Synergistic control of T cell development and tumor suppression by diacylglycerol kinase alpha and zeta. Proc Natl Acad Sci USA 105(33):11909–11914.  https://doi.org/10.1073/pnas.0711856105 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Kortum RL, Rouquette-Jazdanian AK, Miyaji M, Merrill RK, Markegard E, Pinski JM, Wesselink A, Nath NN, Alexander CP, Li W, Kedei N, Roose JP, Blumberg PM, Samelson LE, Sommers CL (2013) A phospholipase C-gamma1-independent, RasGRP1-ERK-dependent pathway drives lymphoproliferative disease in linker for activation of T cells-Y136F mutant mice. J Immunol 190(1):147–158.  https://doi.org/10.4049/jimmunol.1201458 CrossRefPubMedGoogle Scholar
  50. 50.
    Tsun A, Qureshi I, Stinchcombe JC, Jenkins MR, de la Roche M, Kleczkowska J, Zamoyska R, Griffiths GM (2011) Centrosome docking at the immunological synapse is controlled by Lck signaling. J Cell Biol 192(4):663–674.  https://doi.org/10.1083/jcb.201008140 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Immunology and OncologyCentro Nacional de Biotecnología (CNB-CSIC)MadridSpain

Personalised recommendations